Premium
Kynurenic acid synthesis in cerebral cortical slices of rats with progressing symptoms of thioacetamide‐induced hepatic encephalopathy
Author(s) -
Saran Tomasz,
Hilgier Wojciech,
Urbańska Ewa M.,
Turski Waldemar A.,
Albrecht Jan
Publication year - 2003
Publication title -
journal of neuroscience research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.72
H-Index - 160
eISSN - 1097-4547
pISSN - 0360-4012
DOI - 10.1002/jnr.10862
Subject(s) - kynurenic acid , thioacetamide , hepatic encephalopathy , glutamate receptor , medicine , encephalopathy , chemistry , in vivo , kynurenine , pharmacology , endocrinology , biology , receptor , amino acid , biochemistry , cirrhosis , tryptophan , microbiology and biotechnology
Abstract Increased ammonia is a major pathogenic factor in hepatic encephalopathy (HE), a neurologic syndrome associated with glutamatergic dysfunction. Previous studies have shown that in rat cerebral cortical slices or a glia‐derived cell line, acute treatment with ammonia in vitro and in vivo inhibits the production of a broad‐spectrum antagonist of excitatory amino acid receptors, kynurenic acid (KYNA). The present study analyzed KYNA synthesis in cerebral cortical slices obtained from rats with progressing HE symptoms accompanying acute liver failure induced by one, two, or three intraperitoneal administrations of thioacetamide (TAA) at 24‐hr intervals. KYNA synthesis was found decreased to 83% of control 24 hr after one administration of TAA and unaffected after two TAA injections, when moderate hyperammonemia was associated by metabolic and bioelectric activation of the central nervous system, but was not accompanied by typical HE symptoms. KYNA synthesis was elevated to 155% of control after three TAA administrations, a period in which the rats showed advanced HE symptoms including stupor or coma. KYNA synthesis at the advanced HE stage was inhibited by glutamate in a degree comparable to that observed in control slices. The elevation of KYNA synthesis was associated with increased activity of a kynurenine aminotransferase (KAT) isomer, KAT‐II. KYNA synthesis did not differ from control 21 days after the third TAA administration when HE symptoms receded. The results suggest that alterations of KYNA synthesis may contribute to the imbalance between neural excitation and inhibition at different stages of HE. © 2003 Wiley‐Liss, Inc.